Large B-cell Lymphoma Clinical Trials in San Antonio, Texas

4 studies are recruiting for large b-cell lymphoma in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ I…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Texas Transplant Institute, San Antonio, Texas
    Locations
    83 in total
    Run by
    Allogene Therapeutics
  2. Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

    This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell ly…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Texas Transplant Institute, San Antonio, Texas
    Locations
    35 in total
    Run by
    Lyell Immunopharma, Inc.
  3. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Texas Transplant Institute, San Antonio, Texas
    Locations
    36 in total
    Run by
    Lyell Immunopharma, Inc.
  4. A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

    This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    SCRI, San Antonio, Texas
    Locations
    7 in total
    Run by
    CRISPR Therapeutics AG

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.